Perspective Therapeutics, Inc., a biotechnology company, is pioneering the development of the next generation of precision-targeted alpha therapies for oncology. The company's proprietary TAT (Targeted Alpha Therapy) platform is designed to deliver alpha-emitting radiopharmaceuticals directly to cancer cells, minimizing damage to healthy tissue. Two primary products under development by Perspective Therapeutics are VMT-α-NET and VMT01. VMT-α-NET is a TAT designed for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing...
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | ABT | Abbott Laboratories | 177.36 Bn | 27.31 | 4.00 | 12.93 Bn |
| 2 | SYK | Stryker Corp | 124.60 Bn | 38.40 | 4.96 | 15.86 Bn |
| 3 | MDT | Medtronic plc | 109.93 Bn | 23.82 | 3.10 | 28.07 Bn |
| 4 | BSX | Boston Scientific Corp | 93.15 Bn | 31.94 | 4.64 | 11.44 Bn |
| 5 | EW | Edwards Lifesciences Corp | 46.49 Bn | 43.68 | 7.66 | 0.60 Bn |
| 6 | PHG | Koninklijke Philips Nv | 29.40 Bn | 25.00 | 1.46 | 9.41 Bn |
| 7 | DXCM | Dexcom Inc | 24.14 Bn | 28.78 | 5.18 | - |
| 8 | STE | STERIS plc | 21.56 Bn | 30.26 | 3.70 | 1.90 Bn |